Pharma & Healthcare
Global Biopharmaceuticals for Psoriasis Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 569215
- Pages: 150
- Figures: 149
- Views: 7
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Biopharmaceuticals for Psoriasis market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Amgen
Eli Lilly
Johnson & Johnson
Pfizer
AbbVie
Organon
UCB
Segment by Type
TNF-α
Interleukin-17
Interleukin-23
Other
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Biopharmaceuticals for Psoriasis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Biopharmaceuticals for Psoriasis market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Amgen
Eli Lilly
Johnson & Johnson
Pfizer
AbbVie
Organon
UCB
Segment by Type
TNF-α
Interleukin-17
Interleukin-23
Other
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Biopharmaceuticals for Psoriasis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Biopharmaceuticals for Psoriasis: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biopharmaceuticals for Psoriasis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 TNF-α
1.2.3 Interleukin-17
1.2.4 Interleukin-23
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Biopharmaceuticals for Psoriasis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biopharmaceuticals for Psoriasis Revenue Estimates and Forecasts 2020-2031
2.2 Global Biopharmaceuticals for Psoriasis Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Biopharmaceuticals for Psoriasis Sales Estimates and Forecasts 2020-2031
2.4 Global Biopharmaceuticals for Psoriasis Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Biopharmaceuticals for Psoriasis Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Biopharmaceuticals for Psoriasis Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 TNF-α Market Size by Manufacturers
3.5.2 Interleukin-17 Market Size by Manufacturers
3.5.3 Interleukin-23 Market Size by Manufacturers
3.5.4 Other Market Size by Manufacturers
3.6 Global Biopharmaceuticals for Psoriasis Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Biopharmaceuticals for Psoriasis Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Biopharmaceuticals for Psoriasis Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Biopharmaceuticals for Psoriasis Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Biopharmaceuticals for Psoriasis Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
6.4 North America Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Biopharmaceuticals for Psoriasis Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
7.4 Europe Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Biopharmaceuticals for Psoriasis Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Biopharmaceuticals for Psoriasis Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
9.4 Central and South America Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Biopharmaceuticals for Psoriasis Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Biopharmaceuticals for Psoriasis Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Business Overview
11.1.3 Amgen Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.1.4 Amgen Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Amgen Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.1.6 Amgen Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.1.7 Amgen Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.1.8 Amgen Biopharmaceuticals for Psoriasis SWOT Analysis
11.1.9 Amgen Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.2.4 Eli Lilly Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.2.6 Eli Lilly Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.2.7 Eli Lilly Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.2.8 Eli Lilly Biopharmaceuticals for Psoriasis SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.3.4 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.3.6 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.3.7 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.3.8 Johnson & Johnson Biopharmaceuticals for Psoriasis SWOT Analysis
11.3.9 Johnson & Johnson Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.4.4 Pfizer Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Pfizer Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.4.6 Pfizer Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.4.7 Pfizer Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.4.8 Pfizer Biopharmaceuticals for Psoriasis SWOT Analysis
11.4.9 Pfizer Recent Developments
11.5 AbbVie
11.5.1 AbbVie Corporation Information
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.5.4 AbbVie Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 AbbVie Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.5.6 AbbVie Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.5.7 AbbVie Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.5.8 AbbVie Biopharmaceuticals for Psoriasis SWOT Analysis
11.5.9 AbbVie Recent Developments
11.6 Organon
11.6.1 Organon Corporation Information
11.6.2 Organon Business Overview
11.6.3 Organon Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.6.4 Organon Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Organon Recent Developments
11.7 UCB
11.7.1 UCB Corporation Information
11.7.2 UCB Business Overview
11.7.3 UCB Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.7.4 UCB Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 UCB Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Biopharmaceuticals for Psoriasis Industry Chain
12.2 Biopharmaceuticals for Psoriasis Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Biopharmaceuticals for Psoriasis Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Biopharmaceuticals for Psoriasis Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Biopharmaceuticals for Psoriasis Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Biopharmaceuticals for Psoriasis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Biopharmaceuticals for Psoriasis: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biopharmaceuticals for Psoriasis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 TNF-α
1.2.3 Interleukin-17
1.2.4 Interleukin-23
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Biopharmaceuticals for Psoriasis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biopharmaceuticals for Psoriasis Revenue Estimates and Forecasts 2020-2031
2.2 Global Biopharmaceuticals for Psoriasis Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Biopharmaceuticals for Psoriasis Sales Estimates and Forecasts 2020-2031
2.4 Global Biopharmaceuticals for Psoriasis Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Biopharmaceuticals for Psoriasis Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Biopharmaceuticals for Psoriasis Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 TNF-α Market Size by Manufacturers
3.5.2 Interleukin-17 Market Size by Manufacturers
3.5.3 Interleukin-23 Market Size by Manufacturers
3.5.4 Other Market Size by Manufacturers
3.6 Global Biopharmaceuticals for Psoriasis Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Biopharmaceuticals for Psoriasis Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Biopharmaceuticals for Psoriasis Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Biopharmaceuticals for Psoriasis Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Biopharmaceuticals for Psoriasis Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
6.4 North America Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Biopharmaceuticals for Psoriasis Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
7.4 Europe Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Biopharmaceuticals for Psoriasis Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Biopharmaceuticals for Psoriasis Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
9.4 Central and South America Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Biopharmaceuticals for Psoriasis Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Biopharmaceuticals for Psoriasis Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Biopharmaceuticals for Psoriasis Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Biopharmaceuticals for Psoriasis Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Business Overview
11.1.3 Amgen Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.1.4 Amgen Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Amgen Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.1.6 Amgen Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.1.7 Amgen Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.1.8 Amgen Biopharmaceuticals for Psoriasis SWOT Analysis
11.1.9 Amgen Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.2.4 Eli Lilly Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.2.6 Eli Lilly Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.2.7 Eli Lilly Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.2.8 Eli Lilly Biopharmaceuticals for Psoriasis SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.3.4 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.3.6 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.3.7 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.3.8 Johnson & Johnson Biopharmaceuticals for Psoriasis SWOT Analysis
11.3.9 Johnson & Johnson Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.4.4 Pfizer Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Pfizer Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.4.6 Pfizer Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.4.7 Pfizer Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.4.8 Pfizer Biopharmaceuticals for Psoriasis SWOT Analysis
11.4.9 Pfizer Recent Developments
11.5 AbbVie
11.5.1 AbbVie Corporation Information
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.5.4 AbbVie Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 AbbVie Biopharmaceuticals for Psoriasis Sales by Product in 2024
11.5.6 AbbVie Biopharmaceuticals for Psoriasis Sales by Application in 2024
11.5.7 AbbVie Biopharmaceuticals for Psoriasis Sales by Geographic Area in 2024
11.5.8 AbbVie Biopharmaceuticals for Psoriasis SWOT Analysis
11.5.9 AbbVie Recent Developments
11.6 Organon
11.6.1 Organon Corporation Information
11.6.2 Organon Business Overview
11.6.3 Organon Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.6.4 Organon Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Organon Recent Developments
11.7 UCB
11.7.1 UCB Corporation Information
11.7.2 UCB Business Overview
11.7.3 UCB Biopharmaceuticals for Psoriasis Product Models, Descriptions and Specifications
11.7.4 UCB Biopharmaceuticals for Psoriasis Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 UCB Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Biopharmaceuticals for Psoriasis Industry Chain
12.2 Biopharmaceuticals for Psoriasis Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Biopharmaceuticals for Psoriasis Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Biopharmaceuticals for Psoriasis Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Biopharmaceuticals for Psoriasis Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Biopharmaceuticals for Psoriasis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Biopharmaceuticals for Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Biopharmaceuticals for Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Biopharmaceuticals for Psoriasis Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Biopharmaceuticals for Psoriasis Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Biopharmaceuticals for Psoriasis Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Biopharmaceuticals for Psoriasis Sales by Region (2020-2025) & (K Units)
Table 8. Global Biopharmaceuticals for Psoriasis Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Biopharmaceuticals for Psoriasis Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Biopharmaceuticals for Psoriasis Sales Share by Manufacturers (2020-2025)
Table 12. Global Biopharmaceuticals for Psoriasis Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Biopharmaceuticals for Psoriasis by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceuticals for Psoriasis as of 2024)
Table 16. Global Biopharmaceuticals for Psoriasis Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Biopharmaceuticals for Psoriasis Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Biopharmaceuticals for Psoriasis Manufacturing Base and Headquarters
Table 19. Global Biopharmaceuticals for Psoriasis Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Biopharmaceuticals for Psoriasis Sales by Type (2020-2025) & (K Units)
Table 23. Global Biopharmaceuticals for Psoriasis Sales by Type (2026-2031) & (K Units)
Table 24. Global Biopharmaceuticals for Psoriasis Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Biopharmaceuticals for Psoriasis Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Biopharmaceuticals for Psoriasis ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Biopharmaceuticals for Psoriasis Sales by Application (2020-2025) & (K Units)
Table 29. Global Biopharmaceuticals for Psoriasis Sales by Application (2026-2031) & (K Units)
Table 30. Biopharmaceuticals for Psoriasis High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Biopharmaceuticals for Psoriasis Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Biopharmaceuticals for Psoriasis Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Biopharmaceuticals for Psoriasis ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Biopharmaceuticals for Psoriasis Growth Accelerators and Market Barriers
Table 37. North America Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Biopharmaceuticals for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Biopharmaceuticals for Psoriasis Growth Accelerators and Market Barriers
Table 40. Europe Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Biopharmaceuticals for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Biopharmaceuticals for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Biopharmaceuticals for Psoriasis Growth Accelerators and Market Barriers
Table 45. Southeast Asia Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Biopharmaceuticals for Psoriasis Investment Opportunities and Key Challenges
Table 47. Central and South America Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Biopharmaceuticals for Psoriasis Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Amgen Corporation Information
Table 51. Amgen Description and Major Businesses
Table 52. Amgen Product Models, Descriptions and Specifications
Table 53. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Amgen Sales Value Proportion by Product in 2024
Table 55. Amgen Sales Value Proportion by Application in 2024
Table 56. Amgen Sales Value Proportion by Geographic Area in 2024
Table 57. Amgen Biopharmaceuticals for Psoriasis SWOT Analysis
Table 58. Amgen Recent Developments
Table 59. Eli Lilly Corporation Information
Table 60. Eli Lilly Description and Major Businesses
Table 61. Eli Lilly Product Models, Descriptions and Specifications
Table 62. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Eli Lilly Sales Value Proportion by Product in 2024
Table 64. Eli Lilly Sales Value Proportion by Application in 2024
Table 65. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 66. Eli Lilly Biopharmaceuticals for Psoriasis SWOT Analysis
Table 67. Eli Lilly Recent Developments
Table 68. Johnson & Johnson Corporation Information
Table 69. Johnson & Johnson Description and Major Businesses
Table 70. Johnson & Johnson Product Models, Descriptions and Specifications
Table 71. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Johnson & Johnson Sales Value Proportion by Product in 2024
Table 73. Johnson & Johnson Sales Value Proportion by Application in 2024
Table 74. Johnson & Johnson Sales Value Proportion by Geographic Area in 2024
Table 75. Johnson & Johnson Biopharmaceuticals for Psoriasis SWOT Analysis
Table 76. Johnson & Johnson Recent Developments
Table 77. Pfizer Corporation Information
Table 78. Pfizer Description and Major Businesses
Table 79. Pfizer Product Models, Descriptions and Specifications
Table 80. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Pfizer Sales Value Proportion by Product in 2024
Table 82. Pfizer Sales Value Proportion by Application in 2024
Table 83. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 84. Pfizer Biopharmaceuticals for Psoriasis SWOT Analysis
Table 85. Pfizer Recent Developments
Table 86. AbbVie Corporation Information
Table 87. AbbVie Description and Major Businesses
Table 88. AbbVie Product Models, Descriptions and Specifications
Table 89. AbbVie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. AbbVie Sales Value Proportion by Product in 2024
Table 91. AbbVie Sales Value Proportion by Application in 2024
Table 92. AbbVie Sales Value Proportion by Geographic Area in 2024
Table 93. AbbVie Biopharmaceuticals for Psoriasis SWOT Analysis
Table 94. AbbVie Recent Developments
Table 95. Organon Corporation Information
Table 96. Organon Description and Major Businesses
Table 97. Organon Product Models, Descriptions and Specifications
Table 98. Organon Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Organon Recent Developments
Table 100. UCB Corporation Information
Table 101. UCB Description and Major Businesses
Table 102. UCB Product Models, Descriptions and Specifications
Table 103. UCB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. UCB Recent Developments
Table 105. Key Raw Materials Distribution
Table 106. Raw Materials Key Suppliers
Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 108. Milestones in Production Technology Evolution
Table 109. Distributors List
Table 110. Market Trends and Market Evolution
Table 111. Market Drivers and Opportunities
Table 112. Market Challenges, Risks, and Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Biopharmaceuticals for Psoriasis Product Picture
Figure 2. Global Biopharmaceuticals for Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. TNF-α Product Picture
Figure 4. Interleukin-17 Product Picture
Figure 5. Interleukin-23 Product Picture
Figure 6. Other Product Picture
Figure 7. Global Biopharmaceuticals for Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Other
Figure 11. Biopharmaceuticals for Psoriasis Report Years Considered
Figure 12. Global Biopharmaceuticals for Psoriasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 14. Global Biopharmaceuticals for Psoriasis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Region (2020-2031)
Figure 16. Global Biopharmaceuticals for Psoriasis Sales (2020-2031) & (K Units)
Figure 17. Global Biopharmaceuticals for Psoriasis Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Biopharmaceuticals for Psoriasis Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Biopharmaceuticals for Psoriasis Sales Volume Market Share in 2024
Figure 20. Global Biopharmaceuticals for Psoriasis Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. TNF-α Revenue Market Share by Manufacturer in 2024
Figure 23. Interleukin-17 Revenue Market Share by Manufacturer in 2024
Figure 24. Interleukin-23 Revenue Market Share by Manufacturer in 2024
Figure 25. Other Revenue Market Share by Manufacturer in 2024
Figure 26. Global Biopharmaceuticals for Psoriasis Sales Market Share by Type (2020-2031)
Figure 27. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Type (2020-2031)
Figure 28. Global Biopharmaceuticals for Psoriasis Sales Market Share by Application (2020-2031)
Figure 29. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Application (2020-2031)
Figure 30. North America Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 31. North America Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 32. North America Top 5 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 33. North America Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 34. North America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 35. North America Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 36. North America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 37. US Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 38. Canada Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 39. Mexico Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 40. Europe Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 41. Europe Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Europe Top 5 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 43. Europe Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2020-2031)
Figure 44. Europe Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 45. Europe Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 46. Europe Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 47. Germany Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 48. France Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 49. U.K. Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 50. Italy Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 51. Russia Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 53. Asia-Pacific Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Asia-Pacific Top 8 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 55. Asia-Pacific Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 56. Asia-Pacific Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 57. Asia-Pacific Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 58. Asia-Pacific Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 59. Indonesia Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 60. Japan Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 61. South Korea Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 62. China Taiwan Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 63. India Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 64. Central and South America Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 65. Central and South America Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 66. Central and South America Top 5 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 67. Central and South America Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 68. Central and South America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 69. Central and South America Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 70. Central and South America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 71. Brazil Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 72. Argentina Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 73. Middle East, and Africa Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 74. Middle East and Africa Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 75. Middle East and Africa Top 5 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 76. Middle East and Africa Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 77. South America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 78. Middle East and Africa Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 79. Middle East and Africa Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 80. GCC Countries Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 81. Turkey Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 82. Egypt Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 83. South Africa Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 84. Biopharmaceuticals for Psoriasis Industry Chain Mapping
Figure 85. Regional Biopharmaceuticals for Psoriasis Manufacturing Base Distribution (%)
Figure 86. Global Biopharmaceuticals for Psoriasis Production Market Share by Region (2020-2031)
Figure 87. Biopharmaceuticals for Psoriasis Production Process
Figure 88. Regional Biopharmaceuticals for Psoriasis Production Cost Structure
Figure 89. Channels of Distribution (Direct Vs Distribution)
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed
Table 1. Global Biopharmaceuticals for Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Biopharmaceuticals for Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Biopharmaceuticals for Psoriasis Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Biopharmaceuticals for Psoriasis Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Biopharmaceuticals for Psoriasis Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Biopharmaceuticals for Psoriasis Sales by Region (2020-2025) & (K Units)
Table 8. Global Biopharmaceuticals for Psoriasis Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Biopharmaceuticals for Psoriasis Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Biopharmaceuticals for Psoriasis Sales Share by Manufacturers (2020-2025)
Table 12. Global Biopharmaceuticals for Psoriasis Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Biopharmaceuticals for Psoriasis by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceuticals for Psoriasis as of 2024)
Table 16. Global Biopharmaceuticals for Psoriasis Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Biopharmaceuticals for Psoriasis Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Biopharmaceuticals for Psoriasis Manufacturing Base and Headquarters
Table 19. Global Biopharmaceuticals for Psoriasis Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Biopharmaceuticals for Psoriasis Sales by Type (2020-2025) & (K Units)
Table 23. Global Biopharmaceuticals for Psoriasis Sales by Type (2026-2031) & (K Units)
Table 24. Global Biopharmaceuticals for Psoriasis Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Biopharmaceuticals for Psoriasis Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Biopharmaceuticals for Psoriasis ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Biopharmaceuticals for Psoriasis Sales by Application (2020-2025) & (K Units)
Table 29. Global Biopharmaceuticals for Psoriasis Sales by Application (2026-2031) & (K Units)
Table 30. Biopharmaceuticals for Psoriasis High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Biopharmaceuticals for Psoriasis Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Biopharmaceuticals for Psoriasis Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Biopharmaceuticals for Psoriasis ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Biopharmaceuticals for Psoriasis Growth Accelerators and Market Barriers
Table 37. North America Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Biopharmaceuticals for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Biopharmaceuticals for Psoriasis Growth Accelerators and Market Barriers
Table 40. Europe Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Biopharmaceuticals for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Biopharmaceuticals for Psoriasis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Biopharmaceuticals for Psoriasis Growth Accelerators and Market Barriers
Table 45. Southeast Asia Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Biopharmaceuticals for Psoriasis Investment Opportunities and Key Challenges
Table 47. Central and South America Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Biopharmaceuticals for Psoriasis Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Biopharmaceuticals for Psoriasis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Amgen Corporation Information
Table 51. Amgen Description and Major Businesses
Table 52. Amgen Product Models, Descriptions and Specifications
Table 53. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Amgen Sales Value Proportion by Product in 2024
Table 55. Amgen Sales Value Proportion by Application in 2024
Table 56. Amgen Sales Value Proportion by Geographic Area in 2024
Table 57. Amgen Biopharmaceuticals for Psoriasis SWOT Analysis
Table 58. Amgen Recent Developments
Table 59. Eli Lilly Corporation Information
Table 60. Eli Lilly Description and Major Businesses
Table 61. Eli Lilly Product Models, Descriptions and Specifications
Table 62. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Eli Lilly Sales Value Proportion by Product in 2024
Table 64. Eli Lilly Sales Value Proportion by Application in 2024
Table 65. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 66. Eli Lilly Biopharmaceuticals for Psoriasis SWOT Analysis
Table 67. Eli Lilly Recent Developments
Table 68. Johnson & Johnson Corporation Information
Table 69. Johnson & Johnson Description and Major Businesses
Table 70. Johnson & Johnson Product Models, Descriptions and Specifications
Table 71. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Johnson & Johnson Sales Value Proportion by Product in 2024
Table 73. Johnson & Johnson Sales Value Proportion by Application in 2024
Table 74. Johnson & Johnson Sales Value Proportion by Geographic Area in 2024
Table 75. Johnson & Johnson Biopharmaceuticals for Psoriasis SWOT Analysis
Table 76. Johnson & Johnson Recent Developments
Table 77. Pfizer Corporation Information
Table 78. Pfizer Description and Major Businesses
Table 79. Pfizer Product Models, Descriptions and Specifications
Table 80. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Pfizer Sales Value Proportion by Product in 2024
Table 82. Pfizer Sales Value Proportion by Application in 2024
Table 83. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 84. Pfizer Biopharmaceuticals for Psoriasis SWOT Analysis
Table 85. Pfizer Recent Developments
Table 86. AbbVie Corporation Information
Table 87. AbbVie Description and Major Businesses
Table 88. AbbVie Product Models, Descriptions and Specifications
Table 89. AbbVie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. AbbVie Sales Value Proportion by Product in 2024
Table 91. AbbVie Sales Value Proportion by Application in 2024
Table 92. AbbVie Sales Value Proportion by Geographic Area in 2024
Table 93. AbbVie Biopharmaceuticals for Psoriasis SWOT Analysis
Table 94. AbbVie Recent Developments
Table 95. Organon Corporation Information
Table 96. Organon Description and Major Businesses
Table 97. Organon Product Models, Descriptions and Specifications
Table 98. Organon Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Organon Recent Developments
Table 100. UCB Corporation Information
Table 101. UCB Description and Major Businesses
Table 102. UCB Product Models, Descriptions and Specifications
Table 103. UCB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. UCB Recent Developments
Table 105. Key Raw Materials Distribution
Table 106. Raw Materials Key Suppliers
Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 108. Milestones in Production Technology Evolution
Table 109. Distributors List
Table 110. Market Trends and Market Evolution
Table 111. Market Drivers and Opportunities
Table 112. Market Challenges, Risks, and Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Biopharmaceuticals for Psoriasis Product Picture
Figure 2. Global Biopharmaceuticals for Psoriasis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. TNF-α Product Picture
Figure 4. Interleukin-17 Product Picture
Figure 5. Interleukin-23 Product Picture
Figure 6. Other Product Picture
Figure 7. Global Biopharmaceuticals for Psoriasis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Other
Figure 11. Biopharmaceuticals for Psoriasis Report Years Considered
Figure 12. Global Biopharmaceuticals for Psoriasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 14. Global Biopharmaceuticals for Psoriasis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Region (2020-2031)
Figure 16. Global Biopharmaceuticals for Psoriasis Sales (2020-2031) & (K Units)
Figure 17. Global Biopharmaceuticals for Psoriasis Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Biopharmaceuticals for Psoriasis Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Biopharmaceuticals for Psoriasis Sales Volume Market Share in 2024
Figure 20. Global Biopharmaceuticals for Psoriasis Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. TNF-α Revenue Market Share by Manufacturer in 2024
Figure 23. Interleukin-17 Revenue Market Share by Manufacturer in 2024
Figure 24. Interleukin-23 Revenue Market Share by Manufacturer in 2024
Figure 25. Other Revenue Market Share by Manufacturer in 2024
Figure 26. Global Biopharmaceuticals for Psoriasis Sales Market Share by Type (2020-2031)
Figure 27. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Type (2020-2031)
Figure 28. Global Biopharmaceuticals for Psoriasis Sales Market Share by Application (2020-2031)
Figure 29. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Application (2020-2031)
Figure 30. North America Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 31. North America Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 32. North America Top 5 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 33. North America Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 34. North America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 35. North America Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 36. North America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 37. US Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 38. Canada Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 39. Mexico Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 40. Europe Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 41. Europe Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Europe Top 5 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 43. Europe Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2020-2031)
Figure 44. Europe Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 45. Europe Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 46. Europe Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 47. Germany Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 48. France Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 49. U.K. Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 50. Italy Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 51. Russia Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 53. Asia-Pacific Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Asia-Pacific Top 8 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 55. Asia-Pacific Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2020- 2031)
Figure 56. Asia-Pacific Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 57. Asia-Pacific Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 58. Asia-Pacific Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 59. Indonesia Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 60. Japan Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 61. South Korea Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 62. China Taiwan Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 63. India Biopharmaceuticals for Psoriasis Revenue (2020-2031) & (US$ Million)
Figure 64. Central and South America Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 65. Central and South America Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 66. Central and South America Top 5 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 67. Central and South America Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 68. Central and South America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 69. Central and South America Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 70. Central and South America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 71. Brazil Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 72. Argentina Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 73. Middle East, and Africa Biopharmaceuticals for Psoriasis Sales YoY (2020-2031) & (K Units)
Figure 74. Middle East and Africa Biopharmaceuticals for Psoriasis Revenue YoY (2020-2031) & (US$ Million)
Figure 75. Middle East and Africa Top 5 Manufacturers Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) in 2024
Figure 76. Middle East and Africa Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Type (2021-2031)
Figure 77. South America Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 78. Middle East and Africa Biopharmaceuticals for Psoriasis Sales Volume (K Units) by Application (2020-2031)
Figure 79. Middle East and Africa Biopharmaceuticals for Psoriasis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 80. GCC Countries Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 81. Turkey Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 82. Egypt Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 83. South Africa Biopharmaceuticals for Psoriasis Revenue (2020-2025) & (US$ Million)
Figure 84. Biopharmaceuticals for Psoriasis Industry Chain Mapping
Figure 85. Regional Biopharmaceuticals for Psoriasis Manufacturing Base Distribution (%)
Figure 86. Global Biopharmaceuticals for Psoriasis Production Market Share by Region (2020-2031)
Figure 87. Biopharmaceuticals for Psoriasis Production Process
Figure 88. Regional Biopharmaceuticals for Psoriasis Production Cost Structure
Figure 89. Channels of Distribution (Direct Vs Distribution)
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232